Belantamab mafodotin

• Description :

  Belantamab mafodotin (GSK2857916) is composed of humanized and focused monoclonal antibody against B cell maturation antigen (BCMA) and McMMAF. The antibody portion is Belantamab (HY-P9980), and the drug-linker conjugate for ADC is McMMAF (HY-15578) . Belantamab mafodotin has anti-myeloma activity[1][2].

• Product Name Alternative :

  GSK2857916; Belantamab mafodotin-blm

• UNSPSC :

  12352203

• Target :

  Antibody-Drug Conjugates (ADCs)

• Type :

  ADC Related

• Related Pathways :

  Antibody-drug Conjugate/ADC Related

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/belantamab-mafodotin.html

• Purity :

  99.78

• Solubility :

  10 mM in DMSO

• Smiles :

  [Belantamabmafodotin]

• Molecular Weight :

  149000 (average)

• References & Citations :

  [1]Hulin C, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2) : a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21 (2) :207-221.|[2]Markham A. Belantamab Mafodotin: First Approval. Drugs. 2020 Oct;80 (15) :1607-1613.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  -80°C, protect from light

• Scientific Category :

  ADC Related

• Clinical Information :

  Launched

• CAS Number :

  [2050232-20-5]